Michail Ignatiadis, Director of Breast Medical Oncology Clinic and Program at Jules Bordet Institute, shared a post on LinkedIn:
“Why adjuvant palbociclib has not improved outcomes for women with high-risk early breast cancer?
Check out our recent publication.
Leveraging single RNAseq and ATAC seq analysis of pre- and post-treatment tumor samples from the NeoRHEA trial, we provide evidence that palbociclib combined with endocrine therapy suppresses adaptive anti-tumor immunity by reducing T-cell proliferation and depleting tissue-resident memory T cells, which play a central role in long-term immune surveillance.
Our findings have significant implications for the development of next-generation CDK4 inhibitors!”
Title: Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study
Authors: Andreas Papagiannis, Samira Majjaj, Francois P. Duhoux, Elisa Agostinetto, Alexandra M. Stanciu, Thila Vanhulst, Laurence Buisseret, Denis Larsimont, Isabelle Veys, Marianne Paesmans, Tatiana Besse Hammer, Ahmad Awada, Lieveke Ameye, Francoise Rothe, Francesc Madriles, Timothy P. Cash, Roberto Salgado, Karen Willard-Gallo, Christos Sotiriou, Peter Vuylsteke, Patrick Neven, Michail Ignatiadis
Read The Full Article on Nature Communications
More posts featuring Michail Ignatiadis on OncoDaily.